Nebenwirkungen · Comirnaty
Comirnaty JN.1 10 micrograms/dose concentrate for dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 45
HOS-148952 · Präparat HOS-099980
Children 5 to 11 years of age (i.e. 5 to less than 12 years of age) – after the booster (fourth dose) In a subset from Study 6 (Phase 3), 113 participants 5 to 11 years of age who had completed 3 doses of Comirnaty, received a booster (fourth dose) of Comirnaty Original/Omicron BA.4-5 (5/5 mcg) 2.6 to 8.5 months after receiving Dose 3. Participants who received a booster (fourth dose) of Comirnaty Original/Omicron BA.4-5 had a median follow-up time of 6.3 months.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage c5620d017e48bfd61b2174ea90183863d7cac9f1235ac8c9f790d8d780143517 · Zeichen 9448–9915 im Abschnitt